These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 21339490

  • 1. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.
    Soliven B, Miron V, Chun J.
    Neurology; 2011 Feb 22; 76(8 Suppl 3):S9-14. PubMed ID: 21339490
    [Abstract] [Full Text] [Related]

  • 2. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
    Hla T, Brinkmann V.
    Neurology; 2011 Feb 22; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
    [Abstract] [Full Text] [Related]

  • 3. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
    Groves A, Kihara Y, Chun J.
    J Neurol Sci; 2013 May 15; 328(1-2):9-18. PubMed ID: 23518370
    [Abstract] [Full Text] [Related]

  • 4. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A.
    Neurology; 2011 Feb 22; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA, Chun J.
    Ann Neurol; 2011 May 22; 69(5):759-77. PubMed ID: 21520239
    [Abstract] [Full Text] [Related]

  • 6. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Lee CW, Choi JW, Chun J.
    Arch Pharm Res; 2010 Oct 22; 33(10):1567-74. PubMed ID: 21052934
    [Abstract] [Full Text] [Related]

  • 7. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
    Chun J, Hartung HP.
    Clin Neuropharmacol; 2010 Oct 22; 33(2):91-101. PubMed ID: 20061941
    [Abstract] [Full Text] [Related]

  • 8. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
    Baumruker T, Billich A, Brinkmann V.
    Expert Opin Investig Drugs; 2007 Mar 22; 16(3):283-9. PubMed ID: 17302523
    [Abstract] [Full Text] [Related]

  • 9. Impact of sphingosine 1-phosphate modulation on immune outcomes.
    Pinschewer DD, Brinkmann V, Merkler D.
    Neurology; 2011 Feb 22; 76(8 Suppl 3):S15-9. PubMed ID: 21339486
    [Abstract] [Full Text] [Related]

  • 10. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.
    Camm J, Hla T, Bakshi R, Brinkmann V.
    Am Heart J; 2014 Nov 22; 168(5):632-44. PubMed ID: 25440790
    [Abstract] [Full Text] [Related]

  • 11. Central effects of fingolimod.
    Cruz VT, Fonseca J.
    Rev Neurol; 2014 Aug 01; 59(3):121-8. PubMed ID: 25030072
    [Abstract] [Full Text] [Related]

  • 12. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
    Tar L, Vécsei L.
    Ideggyogy Sz; 2012 Mar 30; 65(3-4):83-100. PubMed ID: 23136726
    [Abstract] [Full Text] [Related]

  • 13. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
    Shmyrev VI, Kryzhanovskiĭ SM, Danilycheva IV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012 Mar 30; 112(2 Pt 2):93-7. PubMed ID: 22677684
    [Abstract] [Full Text] [Related]

  • 14. Targeting sphingosine-1-phosphate in hematologic malignancies.
    Stevenson CE, Takabe K, Nagahashi M, Milstien S, Spiegel S.
    Anticancer Agents Med Chem; 2011 Nov 30; 11(9):794-8. PubMed ID: 21707492
    [Abstract] [Full Text] [Related]

  • 15. Modulation of sphingosine 1-phosphate signaling in neurologic disease.
    Antel J, Hohlfeld R.
    Neurology; 2011 Feb 22; 76(8 Suppl 3):S1-2. PubMed ID: 21360856
    [No Abstract] [Full Text] [Related]

  • 16. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.
    Kipp M, Amor S.
    Mult Scler; 2012 Mar 22; 18(3):258-63. PubMed ID: 22383435
    [Abstract] [Full Text] [Related]

  • 17. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V.
    Br J Pharmacol; 2009 Nov 22; 158(5):1173-82. PubMed ID: 19814729
    [Abstract] [Full Text] [Related]

  • 18. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
    Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, Mir A.
    Pharmacol Ther; 2008 Jan 22; 117(1):77-93. PubMed ID: 17961662
    [Abstract] [Full Text] [Related]

  • 19. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
    Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, Chun J.
    Proc Natl Acad Sci U S A; 2011 Jan 11; 108(2):751-6. PubMed ID: 21177428
    [Abstract] [Full Text] [Related]

  • 20. Second generation S1P pathway modulators: research strategies and clinical developments.
    Bigaud M, Guerini D, Billich A, Bassilana F, Brinkmann V.
    Biochim Biophys Acta; 2014 May 11; 1841(5):745-58. PubMed ID: 24239768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.